Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Aug 2023

Goulart Bernardo H L, Larkins Erin, Beaver Julia A, Singh Harpreet

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 37290026
DOI: 10.1200/JCO.23.00154

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations.PMID 37290026Read ↗

Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors?Semantic proximity Read ↗

Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations.Semantic proximity Read ↗

Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials.Semantic proximity Read ↗

Is there a role for first generation TKIs in adjuvant setting of EGFR mutated early NSCLC?Semantic proximity Read ↗

Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.Semantic proximity Read ↗

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?Semantic proximity Read ↗

[I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].Semantic proximity Read ↗

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.Semantic proximity Read ↗

Protein kinase inhibitors to treat non-small-cell lung cancerSemantic proximity Read ↗

Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.Semantic proximity Read ↗

Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?Semantic proximity Read ↗

Efficacy and safety of third-generation EGFR-TKIs in patients with non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.